The level of concern surrounding the budget impact of acute myeloid leukemia (AML) has traditionally been low due to the relatively small size of the population in comparison to solid tumors, the high severity of the disease, and a lack of branded treatment options. As a result, few access controls are utilized for AML therapies. However, with several AML medications recently gaining approval, and many more in the late- stage pipeline, many interviewed payers express concern about the potentially growing budget impact of the indication in the future.

This Datamonitor Healthcare report contains a Pricing & Reimbursement module.